氯吡格雷是急性冠状动脉综合征（ACS）和经皮冠状动脉介入术（PCI）后抗血小板的基础药物，其临床效应在不同患者间存在明显的个体差异。基因多态性可以解释10%～50%氯吡格雷个体间的差异，而CES1参与了氯吡格雷的主要失活途径。目前研究报道的CES1基因多态性主要是CES1 G143E、CES1A2 A（-816）C和CES1 S75N。主要综述CES1基因多态性与氯吡格雷疗效个体差异相关性的研究进展。

Clopidogrel is a primary antiplatelet agent after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). There are significant individual differences in its clinical effect among different patients. Genetic polymorphism can explain between 10% and 50% of the differences in clopidogrel between individuals. CES1 was involved in the main inactivation pathway of clopidogrel. Genetic polymorphisms of CES1 mostly reported were CES1 G143E, CES1A2 A(– 816)C, and CES1 S75N. Research progress on correlation between CES1 gene polymorphisms and the individual differences in the efficacy of clopidogrel is reviewed in this paper.

R968

山东省自然科学基金资助项目（ZR2018PH044）；山东省医药卫生科技发展计划项目（2017WS371）